TY - JOUR
T1 - The Chicago Consensus on peritoneal surface malignancies
T2 - Standards
AU - Chicago Consensus Working Group
AU - Plana, Alejandro
AU - Izquierdo, Francisco J.
AU - Schuitevoerder, Darryl
AU - Abbott, Daniel E.
AU - Abdel-Misih, Sherif
AU - Ahrendt, Steven A.
AU - Al-Kasspooles, Mazin
AU - Amersi, Farin
AU - Arrington, Amanda K.
AU - Badgwell, Brian
AU - Barone, Robert M.
AU - Baumgartner, Joel M.
AU - Berri, Richard N.
AU - Bijelic, Lana
AU - Bowne, Wilbur B.
AU - Blazer, Dan G.
AU - Brown, Charles Komen
AU - Catenacci, Daniel V.
AU - Chan, Carlos H.F.
AU - Cho, Clifford S.
AU - Choudry, M. Haroon A.
AU - Clarke, Callisia N.
AU - Cusack, James C.
AU - Dachman, Abraham H.
AU - Deneve, Jeremiah L.
AU - Dineen, Sean P.
AU - Eng, Oliver S.
AU - Fernandez, Leopoldo J.
AU - Fleshman, James
AU - Clark Gamblin, T.
AU - Gangi, Alexandra
AU - Georgakis, Georgios V.
AU - Gilbert, Erin W.
AU - Goodman, Martin D.
AU - Govindarajan, Anand
AU - Grotz, Travis E.
AU - Gushchin, Vadim
AU - Hanna, Nader
AU - Harmath, Carla
AU - Hart, John
AU - Hayes-Jordan, Andrea
AU - Husain, Aliya N.
AU - Idrees, Kamran
AU - Ihemelandu, Chukwuemeka
AU - In, Haejin
AU - Johnston, Fabian M.
AU - Jiang, David
AU - Kane, John M.
AU - Karakousis, Giorgos
AU - Merkow, Ryan P.
N1 - Funding Information:
James C. Cusack reports grants from Lumicell, Inc, outside the submitted work. Carla Harmath serves on the medical advisory council of Accumen. Hedy Kindler reports personal fees and nonfinancial support from Inventiva, AstraZeneca, Boehringer Ingelheim, Merck, and Paredox; personal fees from Aldeyra Therapeutics, Bayer, Bristol‐Myers Squibb, Erytech, Five Prime Therapeutics, Ipsen Pharmaceuticals, Kyowa, and MedImmune; and funds to support clinical trials at her institution from Aduro, AstraZeneca, Bayer, Bristol‐Myers Squibb, Deciphera, GlaxoSmithKline, Lilly, Merck, MedImmune, Polaris, Verastem, and Blueprint, all outside the submitted work. Garrett M. Nash reports nonfinancial support from Intuitive outside the submitted work. Aytekin Oto reports grants from Philips Healthcare, Guerbet, and Profound Healthcare and serves as a medical advisory board member for Profound Healthcare, all outside the submitted work. Nita Ahuja reports grant funding from Cepheid and Astex, has served as a consultant to Ethicon, and has licensed methylation biomarkers to Cepheid. Jesus Esquivel reports personal fees from Eight Medical. The other authors made no disclosures.
Funding Information:
Funded by the Irving Harris Foundation and the University of Chicago.
Publisher Copyright:
© 2020 by the American Cancer Society and Society of Surgical Oncology
PY - 2020/6/1
Y1 - 2020/6/1
N2 - The Chicago Consensus Working Group provides the following multidisciplinary recommendations for the care of patients with peritoneal surface malignancies. This article focuses on the standards of a peritoneal surface malignancy center, standards of billing and coding, standards of operative reports for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, standards of cytoreductive surgery training, and standards of intraoperative chemotherapy preparation. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
AB - The Chicago Consensus Working Group provides the following multidisciplinary recommendations for the care of patients with peritoneal surface malignancies. This article focuses on the standards of a peritoneal surface malignancy center, standards of billing and coding, standards of operative reports for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, standards of cytoreductive surgery training, and standards of intraoperative chemotherapy preparation. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence.
KW - consensus
KW - neoplasm metastasis
KW - peritoneal neoplasms
KW - standard of care
UR - http://www.scopus.com/inward/record.url?scp=85084610159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084610159&partnerID=8YFLogxK
U2 - 10.1002/cncr.32825
DO - 10.1002/cncr.32825
M3 - Article
C2 - 32282066
AN - SCOPUS:85084610159
SN - 0008-543X
VL - 126
SP - 2516
EP - 2524
JO - Cancer
JF - Cancer
IS - 11
ER -
